[go: up one dir, main page]

PE20070018A1 - Compuestos heterociclicos como inhibidores de aspartil proteasas - Google Patents

Compuestos heterociclicos como inhibidores de aspartil proteasas

Info

Publication number
PE20070018A1
PE20070018A1 PE2006000661A PE2006000661A PE20070018A1 PE 20070018 A1 PE20070018 A1 PE 20070018A1 PE 2006000661 A PE2006000661 A PE 2006000661A PE 2006000661 A PE2006000661 A PE 2006000661A PE 20070018 A1 PE20070018 A1 PE 20070018A1
Authority
PE
Peru
Prior art keywords
aspartile
proteases
inhibitors
compounds
heterocyclic compounds
Prior art date
Application number
PE2006000661A
Other languages
English (en)
Inventor
Andrew Stamford
Zhaoning Zhu
Brian A Mckittrick
Elizabeth M Smith
Ying Huang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20070018A1 publication Critical patent/PE20070018A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REIFERE A COMPUESTOS DE FORMULA (I) DONDE W ES UN ENLACE, -S(O)-, -S(O)2-, -C(=O)-, -O-, ENTRE OTROS; U ES UN ENLACE, -S(O)-, -S(O)2-, -C(O)-, ENTRE OTROS; R ES H, ALQUILO(C1-C20), ARILALQUILO, NO2, ENTRE OTROS; R1 Y R2 SON ALQUILENO, ARILALQUILENO, ENTRE OTROS, O JUNTOS SON UNA CADENA DE (C2-C6) OPCIONALMENTE SUSTITUIDO CON O, C(O), C(S), S(O), ENTRE OTROS; R3 Y R4 SON H, ALQUILO(C1-C20), ARILALQUILO(C6-C14), ARILO(C6-C14), HALO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3'-(4,4-DIFLUORO-8-METIL-2,7-DIOXO-2,4,5,7,8,9-HEXAHIDROIMIDAZO-[2,1-d]-[1,3,5]OXADIAZEPIN-8-IL)-1,1'-BIFENIL-3-CARBONITRILO, 3'-[8-METIL-3-(METILSULFONIL)-2,7-DIOXO-2,4,5,7,8,9-HEXAHIDROIMIDAZO-[1,2-a][1,3,5]TRIAZEPIN-8-IL)-1,1'-BIFENIL-3-CARBONITRILO, 2,2-DIFENIL-1,5,6,7-TETRAHIDROIMIDAZOL[1,2-a]PIRIMIDIN-3-ONA, ENTRE OTROS SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE ASPARTIL PROTEASAS SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES TAL COMO HIPERTENSION, INSUFICIENCIA CARDIACA CONGESTIVA, ENFERMEDADES COGNITIVAS Y NEURODEGENERATIVAS TAL COMO ENFERMEDAD DE ALZHEIMER
PE2006000661A 2005-06-14 2006-06-13 Compuestos heterociclicos como inhibidores de aspartil proteasas PE20070018A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69032605P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
PE20070018A1 true PE20070018A1 (es) 2007-03-08

Family

ID=37074234

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000661A PE20070018A1 (es) 2005-06-14 2006-06-13 Compuestos heterociclicos como inhibidores de aspartil proteasas

Country Status (18)

Country Link
US (1) US7759354B2 (es)
EP (1) EP1896477B1 (es)
JP (1) JP2008543840A (es)
KR (1) KR20080031189A (es)
CN (1) CN101198609A (es)
AR (1) AR054620A1 (es)
AT (1) ATE482214T1 (es)
AU (1) AU2006259675A1 (es)
CA (1) CA2610812A1 (es)
DE (1) DE602006017073D1 (es)
ES (1) ES2350854T3 (es)
HK (1) HK1109151A1 (es)
IL (1) IL187623A0 (es)
MX (1) MX2007016175A (es)
PE (1) PE20070018A1 (es)
TW (1) TW200716644A (es)
WO (1) WO2006138192A1 (es)
ZA (1) ZA200710337B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
MX2007016175A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidor de aspartil proteasas.
TW201004961A (en) 2005-06-14 2010-02-01 Schering Corp Aspartyl protease inhibitors
CN101346357B (zh) 2005-10-25 2014-04-02 盐野义制药株式会社 氨基二氢噻嗪衍生物
CN101484429A (zh) 2006-06-12 2009-07-15 先灵公司 杂环的天冬氨酰基蛋白酶抑制剂
CA2672295A1 (en) * 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
EP2689780A1 (en) 2007-04-24 2014-01-29 Shionogi & Co., Ltd. Intermediates for aminodihydrothiazine derivatives substituted with a cyclic group
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
JP2010538068A (ja) 2007-09-06 2010-12-09 シェーリング コーポレイション ガンマセクレターゼモジュレーター
CA2704698A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
EP2227471A1 (en) 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
EP2288613B1 (en) 2008-04-22 2016-07-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
AU2009258496B8 (en) 2008-06-13 2014-06-26 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
WO2010021680A2 (en) * 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
WO2010056849A1 (en) 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators
WO2010075204A2 (en) 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
CA2747744A1 (en) 2008-12-22 2010-07-01 Theodros Asberom Gamma secretase modulators
KR20120001756A (ko) 2009-03-13 2012-01-04 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
EP2443118A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
US20120238546A1 (en) 2009-06-16 2012-09-20 Zhaoning Zhu Gamma secretase modulators
US20120245158A1 (en) 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2485590B1 (en) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA110467C2 (uk) 2009-12-11 2016-01-12 Шионогі Енд Ко., Лтд. Похідні оксазину
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ベータセクレターゼインヒビター
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
JP6482458B2 (ja) 2012-03-19 2019-03-13 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ａｐｐ特異性のｂａｃｅ（ａｓｂｉ）およびその使用
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
EP2900650A1 (en) 2012-09-28 2015-08-05 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EP2908825B1 (en) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2908824B1 (en) 2012-10-17 2018-05-02 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
DK2956443T3 (da) 2013-02-12 2020-01-20 Buck Inst Res Aging Hydantoiner som modulatorer af BACE-medieret APP-forarbejdning
JP6321685B2 (ja) 2013-02-25 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ２−アミノ−３，４−ジヒドロ−キナゾリン誘導体、およびそのカテプシンｄ阻害剤としての使用
US11766435B2 (en) 2016-02-18 2023-09-26 Merck Sharp & Dohme Llc N3-substituted iminopyrimidinones as antimalarial agents

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865836A (en) * 1972-12-08 1975-02-11 Janssen Pharmaceutica Nv Bicyclic imidazoles
JPS5946518B2 (ja) * 1976-12-23 1984-11-13 第一製薬株式会社 ２，２−又は３，３−ジ置換−イミダゾ〔１，２−ａ〕〔１，３〕ジアザシクロアルカン類
GB8312892D0 (en) * 1983-05-11 1983-06-15 Raychem Ltd Electrical insulator
JPS60173546A (ja) * 1984-02-20 1985-09-06 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の現像処理方法
WO1993004047A1 (en) 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
US5958920A (en) * 1994-12-02 1999-09-28 The United States Of America As Represented By The Department Of Health And Human Services Aralkyl diazabicycloalkane derivatives for CNS disorders
EP0918771A4 (en) * 1996-07-15 2001-02-07 Bristol Myers Squibb Co THIADIOXOBENZODIAZEPINES FOR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
FR2756282B1 (fr) * 1996-11-22 1998-12-31 Elf Aquitaine Procede de synthese d'esters de l'acide mercapto-3-propionique
CA2333927A1 (en) * 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
EP1340760A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
EP1340761A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
EP1295885A1 (en) 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
ES2250721T3 (es) * 2001-09-21 2006-04-16 Sanofi-Aventis Derivados de 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona y 7-pirimidinil-2,3-dihidroimidazo(1,2-a)pirimidin-5(1h)ona sustituidos para enfermedades neurodegenerativas.
AU2004263532A1 (en) * 2003-08-08 2005-02-17 Pharmacopeia, Inc. Cyclic amine base-1 inhibitors having a heterocyclic substituent
CN1863797A (zh) * 2003-08-08 2006-11-15 先灵公司 具有苯甲酰胺取代基的环胺bace－1抑制剂
AU2004294933B2 (en) * 2003-11-21 2011-11-17 Johns Hopkins University Biomolecule partition motifs and uses thereof
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
SI1699455T1 (sl) 2003-12-15 2013-10-30 Merck Sharp & Dohme Corp. Heterocikliäśni aspartil proteazni inhibitorji
WO2005073365A1 (ja) 2004-01-29 2005-08-11 Japan Tissue Engineering Co., Ltd. 移植用細胞の処理方法、細胞懸濁液、移植用補綴物、および損傷部位の治療方法
DE102004007076A1 (de) * 2004-02-13 2005-08-25 Bayer Cropscience Ag Imidazolopyrimidine
WO2006009655A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
ES2332659T3 (es) * 2004-06-16 2010-02-10 Wyeth Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa.
JP2008507538A (ja) * 2004-07-22 2008-03-13 シェーリング　コーポレイション 置換アミドβセクレターゼインヒビター
US7652003B2 (en) 2004-07-28 2010-01-26 Schering-Plough Corporation Macrocyclic β-secretase inhibitors
AU2005295814A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of Alzhermer's disease
WO2006041404A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
WO2006089122A2 (en) * 2005-02-18 2006-08-24 North Carolina State University De novo synthesis of bacteriochlorins
MX2007016182A (es) * 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
TW201004961A (en) * 2005-06-14 2010-02-01 Schering Corp Aspartyl protease inhibitors
MX2007016175A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidor de aspartil proteasas.
MX2007016177A (es) * 2005-06-14 2008-03-07 Schering Corp La preparacion y uso de compuestos como inhibidores de aspartil proteasas.
WO2006138230A2 (en) 2005-06-14 2006-12-28 Schering Corporation The preparation and use of protease inhibitors
ES2436795T3 (es) 2005-06-14 2014-01-07 Merck Sharp & Dohme Corp. Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos
US7812013B2 (en) * 2005-06-14 2010-10-12 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
CA2620223A1 (en) * 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
EP1940828B1 (en) 2005-10-27 2010-08-18 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2628264A1 (en) * 2005-10-31 2007-05-10 Schering Corporation Aspartyl protease inhibitors
CA2637565A1 (en) 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
CN101484429A (zh) * 2006-06-12 2009-07-15 先灵公司 杂环的天冬氨酰基蛋白酶抑制剂
CA2669982A1 (en) 2006-11-17 2008-05-29 Schering Corporation Combination therapy for proliferative disorders
CA2672295A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.

Also Published As

Publication number Publication date
EP1896477A1 (en) 2008-03-12
US20060281730A1 (en) 2006-12-14
TW200716644A (en) 2007-05-01
US7759354B2 (en) 2010-07-20
EP1896477B1 (en) 2010-09-22
WO2006138192A1 (en) 2006-12-28
DE602006017073D1 (en) 2010-11-04
KR20080031189A (ko) 2008-04-08
CN101198609A (zh) 2008-06-11
HK1109151A1 (en) 2008-05-30
ATE482214T1 (de) 2010-10-15
AR054620A1 (es) 2007-07-04
IL187623A0 (en) 2008-03-20
CA2610812A1 (en) 2006-12-28
JP2008543840A (ja) 2008-12-04
ES2350854T3 (es) 2011-01-27
ZA200710337B (en) 2008-12-31
MX2007016175A (es) 2008-03-07
AU2006259675A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
PE20070018A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
ATE425166T1 (de) Amidderivate von 3-phenyldihydropyrimidoä4,5- düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20040999A1 (es) Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
PE20041000A1 (es) Pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
NO20065904L (no) Terapeutiske forbindelser
CR8744A (es) Compuestos terapeuticos
SE0200979D0 (sv) New compounds
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
WO2004018475A3 (en) Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
WO2006042950A3 (fr) Utilisation de derives de pyrrolo- pyraz ines pour le traitement de la mucoviscidose
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
NO20063619L (no) Diarylmetylpiperazinderivater, fremstilling og anvendelse derav
PA8589801A1 (es) Aminoalcoxiindoles
AR044083A1 (es) Compuestos con actividad anti-inflamatoria
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
FC Refusal